RxDoctor Payments Data

Carlos Plata, MD

Rheumatology · Amarillo, TXNPI 1508872029

Payments from drug & device makers

$19,931in general payments, 2019–2025

Across 1,251 payments — averaging $15.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$4K
  • AbbVie$2K
  • UCB, Inc.$2K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • GSK$934
  • plus $8K from 34 others

What the payments were for

  • Food & beverage$19,73999%
  • Education$1921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,931 in reported general payments places this provider in the 70th percentile of 512 rheumatology providers in Texas.

See all rheumatology providers in Texas

Medicare billing

Part B allowed, 2024
$2,294,249
Medicare patients
499
Services billed
118,290

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab55$423,923
Enbrel SureclickEtanercept50$366,086
RinvoqUpadacitinib50$336,382
Orencia ClickjectAbatacept32$245,403
Cimzia (2 Pack)Certolizumab Pegol18$111,960
OtezlaApremilast19$98,526
Humira(Cf)Adalimumab12$79,873
SimponiGolimumab11$69,140
ForteoTeriparatide13$64,773
XeljanzTofacitinib Citrate11$60,315
KevzaraSarilumab13$56,753
OxycontinOxycodone Hcl22$25,749
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen418$17,979
Hydroxychloroquine Sulfate289$10,328
MethotrexateMethotrexate Sodium223$5,348

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$2,436$416,25562 claims
UCB, Inc.Cimzia (2 Pack)$2,225$111,96018 claims
AmgenOtezla$3,712$98,52619 claims
Johnson & JohnsonSimponi$1,297$69,14011 claims
Lilly USA, LLCForteo$611$64,77313 claims
PfizerXeljanz$1,114$60,31511 claims
SanofiKevzara$236$56,75313 claims
Scilex Pharmaceuticals Inc.Colchicine$50$2,48447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 512 rheumatology providers in Texas.

Other rheumatology in Amarillo

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →